← Human Trials & Peer-Reviewed Studies
The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized placebo-controlled double-blind study.
Plain-language guide to PMID 1387849 (1992): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin).
Key Facts
- PMID
- 1387849
- Journal
- Fertility and sterility
- Year
- 1992
- Study type
- Randomized Controlled Trial
- Authors
- Younis JS et al. (6 authors)
- DOI
- 10.1016/s0015-0282(16)55266-2
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin), published as a randomized controlled trial.
Who Took Part
By PubMed's age tags, the people studied were adults, women only.
Forty-two normal ovulatory, women who were 38 years of age or less with mechanical factor infertility and a normal male factor were selected for this study.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
Growth hormone or placebo were administered in a prospective randomized double-blind manner.
Ovulation induction with hMG was started 14 days after pituitary down regulation (17 beta-estradiol [E2] serum level less than 30 pg/mL).
What Was Measured
PubMed files the paper under topics including Chorionic Gonadotropin, Embryo Implantation, Embryo Transfer, Estradiol, Fertilization in Vitro, Follicular Phase and Gonadotropin-Releasing Hormone.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin).
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1992 (Fertility and sterility), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the hCG (human chorionic gonadotropin) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
hCG (human chorionic gonadotropin): An LH analog that drives Leydig-cell testosterone production.
HMG (Human Menopausal Gonadotropin): Menotropins: a glycoprotein preparation that supplies follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- hCG (human chorionic gonadotropin) in the library
- HMG (Human Menopausal Gonadotropin) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.